Janux Therapeutics/$JANX
1D1W1MYTD1Y5YMAX
Capital at risk
About Janux Therapeutics
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
- Ticker
- $JANX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 113
- Headquarters
- San Diego, United States
- Website
- www.januxrx.com
JANX Metrics
BasicAdvanced
$1B
-
-$1.64
2.51
-
Price and volume
Market cap
$1B
Beta
2.51
52-week high
$35.34
52-week low
$12.12
Average daily volume
907K
Financial strength
Current ratio
16.348
Quick ratio
16.246
Long term debt to equity
0.02
Total debt to equity
0.023
Profitability
EBITDA (TTM)
-141.654
Gross margin (TTM)
-416.60%
Net profit margin (TTM)
-427.47%
Operating margin (TTM)
-598.15%
Revenue per employee (TTM)
$210,000
Management effectiveness
Return on assets (TTM)
-8.80%
Return on equity (TTM)
-10.70%
Valuation
Price to revenue (TTM)
44.258
Price to book
1.12
Price to tangible book (TTM)
1.12
Price to free cash flow (TTM)
-25.335
Free cash flow yield (TTM)
-3.95%
Free cash flow per share (TTM)
-0.671
Growth
Revenue change (TTM)
5,366.97%
Earnings per share change (TTM)
-8.55%
3-year revenue growth (CAGR)
45.68%
3-year earnings per share growth (CAGR)
0.37%
What the Analysts think about JANX
Analyst ratings (Buy, Hold, Sell) for Janux Therapeutics stock.
Analyst projections of the future price of Janux Therapeutics stock.
Bulls say / Bears say
Early clinical data for JANX007 show a favourable safety profile, with no Grade 3 cytokine release syndrome observed at clinically relevant dose levels under the current mitigation strategy. That could help Janux address a key limitation of T-cell engagers as dose optimisation continues. (Janux Therapeutics)
Janux is building several potential value drivers around PSMA: JANX007 and JANX014 are in clinical studies, while the CD28 programme JANX013 is expected to enter the clinic in the second half of 2026. The company also held $970.9 million in cash, cash equivalents and short-term investments at the end of the second quarter, supporting continued development. (Janux Therapeutics)
The Bristol Myers Squibb collaboration has produced a development-candidate nomination and a $35 million milestone payment. BMS is responsible for later clinical development and global commercialisation, while Janux remains eligible for further milestones and tiered royalties, which could reduce funding pressure and provide external validation. (Janux Therapeutics)
Janux discontinued JANX008 after Phase 1a because the overall magnitude and consistency of activity did not justify further development; the company also cited dose-limiting adverse events. This raises the risk that the platform may not translate consistently across different tumour targets. (Janux Therapeutics)
The main value driver, JANX007, remains in Phase 1b with dose optimisation and ongoing enrolment, and further clinical data are not expected until the first half of 2027. Investors therefore still face a long wait for more mature evidence that its early activity is durable and commercially meaningful. (Janux Therapeutics)
The BMS deal is not yet clinical validation: the partnered target remains undisclosed, Janux is only responsible through preclinical development and IND submission, and BMS takes over subsequent clinical work. The $35 million payment therefore does not remove the risk that the programme fails in human trials. (Janux Therapeutics)
Data summarised monthly by Lightyear AI. Last updated on 20 Sept 2026.
JANX Financial Performance
Revenues and expenses
JANX Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing JANX
AllUSDEURGBP
Fund name | Fund size | $JANX weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.08% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.08% |
iShares Healthcare Innovation£DRDR | £1B | 0.08% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.07% |
iShares Ageing Population€AGED | €822M | 0.07% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.